abbott pois see robust growth diabet care
fda approv freestyl libr
updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim jan
price data jan
rate updat jan
currenc amount express
valuat growth profit
methodolog valu compani
abbott continu remodel acquisit st jude
medic continu improv profit
segment nutrit devic diagnost establish
pharmaceut although abbott made progress sinc
spin-off still lag key rival profit measur
despit compet busi character
abbott effort improv effici includ streamlin
distribut channel build facil lower-cost locat
like china india demonstr success
still room improv look compani
consolid profit think abbott emphasi margin
improv pay next five year
like manag turn attent new sourc
growth think abbott new freestyl libr blood glucos
monitor offer compel innov anticip addit
veropharm provid abbott substanti
footprint latin america russia establish
pharmaceut product applaud sale abbott epp
busi develop market reshuffl put
abbott favor posit benefit stronger demand
brand gener emerg market addit st jude
along smaller tuck-in significantli broaden abbott
cardiac devic product portfolio rais firm abil
compet hospit client seek winnow supplier
continu forecast mid-single-digit revenu growth
abbott think potenti firm goos growth
key product line meantim see opportun
abbott enhanc effici fuel earn growth
address situat low-hang fruit larg
manag control abbott exceed expect
close profit gap competit set upsid
valuat
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
abbott manufactur market medic devic blood glucos
monitor kit nutrit healthcar product diagnost product
equip brand gener drug product includ pacemak
formula nutrit liquid adult vessel closur devic lasik
equip abbott deriv approxim sale outsid unit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit jan
rais fair valu estim per share
reflect cash flow realiz sinc last updat
continu hold optimist expect growth
rhythm manag electrophysiolog
neuromodul product thank new
product launch underli growth demand
expect manag abl meet goal
million cost synergi year four project
revenu growth fuel acquisit st jude
aler averag annual sale growth
stand behind temper project growth
intern nutrit market condit china
remain bumpi competitor work adopt
new regul ultim reduc pool
competitor
still see potenti improv profit abbott
remain busi turn key factor
valuat consolid basi abbott oper
margin significantli trail key competitor
variou busi segment good news abbott
compet sever market offer rel high
margin includ nutrit brand gener drug
cardiovascular devic addit abbott alreadi
begun effort improv product effici
streamlin distribut channel build new facil
lower-cost locat like china india expect
abbott partial close oper margin gap
project basi point improv firm
leverag distribut infrastructur built
penetr emerg market across product
segment extract cost synergi recent
bullish scenario put abbott valu per
share case assum abbott averag
top-lin growth thank addit st jude aler
well outsiz gain pediatr adult nutrit
intern double-digit growth molecular diagnost
greater penetr cardiovascular devic oversea
also assum abbott reach level manufactur
expens compar key competitor
like mead johnson along oper margin peak
bear case abbott per share
scenario top line averag annual follow
addit st jude aler assum
declin stent sale
offer superior technolog mute perform portico
transcathet valv low-single-digit growth nutrit
low-single-digit growth diagnost assum
abbott rais gross margin basi point
think addit st jude push abbott toward
wider side narrow moat fulli convinc
abbott tip wide moat categori
especi firm nurtur kind on-going
occasion revolutionari innov necessari
secur reimburs longer term
case abbott one three four competitor
domin market includ nutrit cardiac
monitor coronari stent immunoassay
market abbott particip ration oligopoli
enjoy benefit intang asset
think nutrit busi one moatiest
part new abbott wield leadership posit
highli consolid market estim
billion world-wide asid strength develop
market firm face brighter growth prospect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
leverag sell fragment market also translat
less price pressur abbott could chang
longer term emerg market turn
tender system character develop nation
howev chang remain
near medium term think abbott benefit
addit st jude impress expertis
cardiac rhythm manag structur heart heart
failur howev juri still abbott abil
nurtur renew innov area long haul
abbott demonstr compet launch
next-gener product lifeblood devic
busi less enthusiast attempt
greater leap innov
final abbott reli intellectu properti ward
competitor devic diagnost segment
think firm earn narrow moat four
segment translat narrow moat entir
potenti price pressur variou sourc
across abbott market exampl trend toward
brand gener declin
reimburs vascular devic firm
invest pipelin lead stream new
product fortifi price power medium
term abbott scale divers help steadi moat
trend anticip strength cardiac devic segment
divis diabet busi off-set
current weak intern nutrit molecular
abbott abil deploy robust predict cash
flow
busi toward acquisit
emerg market growth middle-class
famili spur demand pediatr adult nutrit
product thank strong similac ensur brand
abbott advantag posit introduc new
formul line extens penetr new
market abbott made substanti invest earli
build infrastructur emerg market includ
new ventur new zealand-bas build
large-scal dairi farm hub china firm
reap reward invest expand
build block experi nutrit
also play well appli abbott
establish pharmaceut product segment
mainli sold outsid busi frequent call
brand gener oper like consum busi
tradit brand drug exampl abbott
brand gener mainli sold less develop
market often lack well-develop infrastructur
distribut instead abbott must sell product directli
pharmaci chain physician result brand
recognit reput key factor abbott
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
partnership help replenish pipelin
support abbott growth also keep smaller
compani gain critic mass encroach
abbott narrow moat abbott develop
revolutionari devic pipelin candid demonstr
strongli favor clinic outcom acquir
extens collect med-tech product allow
comprehens partner hospit
consid turn moat trend rate posit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oabbott xienc stent remain powerhous
well-
drug-elut stent market thank
establish record safeti efficaci
oaggress cost-cut plan propel abbott
bottom-lin growth quickli top-lin growth
oabbott sale establish pharma busi
develop market acquisit
veropharm put abbott brand gener
busi strong posit benefit grow
demand emerg market
oclin data drug-elut stent altern
therapi put crimp percutan coronari
procedur medic therapi coronari bypass
gain favor
oabbott face uphil battl molecular
diagnost arena must go head-to-head
market leader roch along energet
upstart like
oconsid heterogen involv mitral valv
diseas skeptic mitraclip move
beyond nich use certain inoper patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
larg acquisit st jude medic aler
abbott enjoy less financi flexibl
medium term issu debt share financ
purchas sale vision-car busi
stake peg debt/ebitda around
manag indic abbott plan de-lever
near term think bring debt level
time end despit increas interest
expens anticip abbott still see adequ
coverag ebitda/interest time
coverag rise ensu year
abbott nutrit unit seem larg impervi
econom cycl think addit st jude increas
abbott exposur vagari cardiac product cycl
clinic trial reimburs issu accordingli
peg abbott uncertainti medium like compani
involv medic technolog abbott vulner
threat revolutionari innov competitor
particularli issu medic devic
diagnost busi despit abbott recent effort
better insul recal like infant formula
recal china risk product qualiti issu
recal remain damag firm brand
relationship medic profession hospit
custom payer tighten purs string abbott could
see greater price pressur furthermor hospit
cardiac therapeut area abbott could find
disadvantag compar key rival
johnson johnson final abbott oper
scrutini food drug administr
well regulatori agenc oversea lead
delay product approv product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
share
fund
share
fund
overal rate abbott stewardship standard
compani made impress purchas
past decad includ purchas
billion brought humira sever
recent acquisit advanc medic optic
piram remain promis yet fulli match
purchas price remain skeptic acquisit
aler point-of-car diagnost seem
add compel valu abbott technolog
distribut bargain posit proprietari
pharma product spun expect
manag new focu remain busi
result greater effici profit
watch care see abbott abl realiz
potenti acquisit made avoid less
mile white took helm ceo chairman
board follow year tenur abbott date
back provid experi need handl
compani mani oper line find somewhat
worrisom white allow non-abbvie-rel
busi becom flabbi watch white
made progress profit front past
sever year still plenti room
improv abbott catch key
competitor board heavili weight
toward independ former execut
publicli trade firm chicago area particularli
pleas see stark former ceo st jude join
board expect experi lead st jude ramp
innov could posit influenc abbott
said think room improv
compens polici -- move away benchmark
involv adjust earn per share ebit
measur focus return invest capit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
result slightli outpac
expect top line slight adjust
assumpt materi enough shift fair valu
estim abbott begun reap reward wax
product cycl year expect continu
thank increas adopt new product
well other deck approv develop
regulatori delay dog st jude medic
iron abbott enjoy
cardiac rhythm
robust stream new product
failur
neuromodul abbott also happen kick new
product cycl alin system diagnost
next-gen xienc sierra coronari stent newli food
drug administration-approv
continu glucos monitor narrow-moat abbott sit
robust collect new technolog readi
commerci expect sustain mid-single-
digit revenu growth
pediatr nutrit remain soft spot relat mostli
perform foreign market consid china
biggest driver portion abbott busi weve
pleas see sign improv condit
market tighter food safeti regul set
januari weve expect
signific consolid fragment market
favor multin larg nativ compani
smaller chines compani find unabl
clear new regulatori hurdl abbott along
multin nativ compani pass
new registr program dont anticip
disrupt commerci program china although
number formul brand extens
limit expect abbott take advantag sell
maximum nine see greater volum smaller
set sku
pleas see manag comment
greater stabil chines infant formula market
corrobor recent posit perform weve seen
rival danon formula busi lead us expect
similarli favor revenu growth abbott chines
pediatr nutrit busi head
saw surpris abbott second-quart
abbott report second-quart result gener met
expect top bottom line howev
modestli rais fair valu estim per
share slight upward adjust project
growth cardiac rhythm manag electrophysiolog
neuromodul product thank new
product launch underli growth demand
think abbott narrow moat remain intact trend
pleas see continu strength domest
pediatr nutrit establish pharmaceut well
core lab point-of-car diagnost drove
quarterli total revenu growth oper
basi within devic divis remain optimist
double-digit growth prospect electrophysiolog
product technolog innov atrial fibril
ablat eas way adopt therapi
pleasantli surpris see robust perform legaci
st jude neuromodul busi strength
new burst stimul manag chronic pain -- year
year unit state clear burst
stimul superior innov spinal cord
stimul market improv tonic
stimul mainstay therapeut
area consid low penetr neuromodul
devic well emerg applic technolog
condit
includ opioid addict
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
believ polit unten republican
allow scenario playout given control everi
branch feder govern signific
percentag affect vote district either republican
tossup lean addit believ congression
gop leadership keen move polit
minefield healthcar legisl toward initi
major overhaul tax code
bottom line believ like remain place
time come domin affect upon
healthcare-rel firm continu howev also
believ need legisl address long-
term issu concern relat certain aspect
law chiefli lawmak formul long-term
plan stabil public exchange/individu market
compris approxim quarter privat
insur space order keep premium cost check
prevent death-spir scenario develop
anticip sustain growth market new
improv indic roll
convers think weak intern
nutrit molecular diagnost could persist
particular formula market china roil
rise regulatori standard smaller competitor
discount product exit mind market may
stabil late
polit realiti much gop healthcar overhaul
mix impact healthcar coverag jul
polit realiti scale back healthcar coverag
million constitu much senat
gop overcom pass major overhaul
afford act loss two ye
vote initi revis senat republican plan
senat major leadership unabl push measur
would appeal moder
libertarian wing caucu thu believ
probabl substant repeal replac plan
becom law extrem low balanc find
develop posit manag care
hospit sector volum increas due expand
coverag remain place end
spectrum elimin variou fee tax
pharmaceut devic compani tabl
even though develop maintain statu quo
oper environ take away potenti
posit financi impact firm
believ senat take step toward
shore weak public exchang marketplac order
near term like requir meaning
level bipartisan negoti chamber congress
despit rhetor let marketplac fail
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
